Gene expression profiling and breast cancer care: What are the potential benefits and policy implications?

Genetics in Medicine

Volumn 7, Issue 6, 2005, Pages 380-389

  Oestreicher, Nina ^a,b,d   Ramsey, Scott D ^a,b   Linden, Hannah M ^a,b   McCune, Jeannine S ^a,b   Van't Veer, Laura J ^c   Burke, Wylie ^a   Veenstra, David L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d DIVISION OF RESEARCH   (United States)

Author keywords

Breast cancer; Cost effectiveness; Gene expression profiling; Genetic tests; Microarray analysis

Indexed keywords

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CARE; CANCER RECURRENCE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION ANALYTIC MODEL; DECISION MAKING; GENE EXPRESSION PROFILING; GENE TECHNOLOGY; HEALTH CARE; HEALTH CARE POLICY; HEALTH INSURANCE; MODEL; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; RISK REDUCTION;

ADULT; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; HEALTH POLICY; HUMANS; MIDDLE AGED; MODELS, ECONOMETRIC; PRACTICE GUIDELINES; QUALITY-ADJUSTED LIFE YEARS; RADIOTHERAPY, ADJUVANT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

EID: 23744459918     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GIM.0000170776.31248.75     Document Type: Article

References (66)

1. Ries LAG, Eisner MP, Kosary CL et al, eds. SEER Cancer Statistics Review, 1975-2001. Bethesda, MD: National Cancer Institute, 2004.
2. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930-942.
3. Shapiro CL, Recht A. Late effects of adjuvant therapy for breast cancer. J Natl Cancer Inst Monog 1994;16:101-112.
4. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001;344:1997-2008.
5. Eifel P, Axelson JA, Costa J et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Ins 2001;93:979-989.
6. National Comprehensive Cancer Network. Update: NCCN practice guidelines for the treatment of breast cancer. National Comprehensive Cancer Network. Oncology (Hunting) 1999;13:41-66.
7. Bast RC, Jr., Ravdin P, Hayes DF et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-1878.
8. Sauter G, Simon R. Predictive molecular pathology. N Engl J Med 2002;347:1995-1996.
9. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
10. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-2826.
11. King HC, Sinha AA. Gene expression profile analysis by DNA microarrays: promise and pitfalls. JAMA 2001;286:2280-2288.
12. Agendia, 2004. Agendia announces a collaboration with MPI, Phoenix, AZ. Available at: http://www.agendia.com/common.asp?id=75&instantie= 0&sContentID= 312-2. Accessed April 4,2005.
13. Ipsogen, 2005. Available at: http://www.ipsogen.com/products/ index_breastcancer.html. Accessed April 4, 2005.
14. Lyman G, Cosler L, Hornberger J. A 21-gene RT-PCR assay in lymph node negative, estrogen receptor positive early-stage breast cancer: an age-specific economic analysis. Paper presented at: San Antonio Breast Cancer Symposium. San Antonio, December 8-11, 2004.
15. van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536.
16. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-338.
17. Gold ME, Russell LB, Siegel JE, Weinstein ME, eds. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
18. National Center for Health Statistics. National Vital Statistics Report, Vol. 50, Number 15, 2002.
19. National Cancer Institute, 2003. Cancer PDQ. Available at: http://www.nci.nih.gov/ cancertopics/pdq/treatment/breast/HealthProfessional/ page8#Section_206. Accessed April 4, 2005.
20. College of American Pathologists, 2005. Getting personal: Cancer assay could provide additional risk of recurrence. Available at: http://www.cap.org/ apps/docs/cap_today/feature_stories/0204Gettingpersonal.html. Accessed April 4, 2005.
21. Oestreicher N. The economic and clinical outcomes and policy implications of gene expression profiling in breast cancer care [dissertation]. Seattle: Department of Pharmacy, University of Washington, 2004.
22. Hartunian NS, Smart CN, Thompson MS. The incidence and economic costs of cancer, motor vehicle injuries, coronary heart disease, and stroke: a comparative analysis. Am J Public Health 1980;70:1249-1260.
23. Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics 1997;53:419-434.
24. Mishel L, Bernstein J, Boushey H. The State of Working America 2002/2003. Ithaca, NY: Cornell University Press, 2003.
25. Drummond M, O'Brien B, Stoddart G, Torrance G. Methods for the Economic Evaluation of Health Care Programmes. New York: Oxford University Press, 1999.
26. Hall J, Gerard K, Salkeld G, Richardson J A cost utility analysis of mammography screening in Australia. Soc Sci Med 1992;34:993-1004.
27. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 1985;5:157-177.
28. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000;17:479-500.
29. Carlson RW, Anderson BO, Bensinger W et al. NCCN Practice Guidelines for Breast Cancer. Oncology (Huntingt) 2000;14:33-49.
30. Bast RC, Jr., Hortobagyi GN. Individualized care for patients with cancer: a work in progress. N Engl J Med 2004;351:2865-2867.
31. Harlan LC, Abrams J, Warren JL, Clegg L, Stevens J, Ballard-Barbash R. Adjuvant therapy for breast cancer: practice patterns of community physicians. J Clin Oncol 2002;20:1809-1817.
32. Du XL, Key CR, Osborne C, Mahnken JD, Goodwin JS. Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med 2003;138:90-97.
33. Barlow WE, Taplin SH, Yoshida CK, Buist DS, Seger D, Brown M. Cost comparison of mastectomy versus breast-conserving therapy for early-stage breast cancer. J Natl Cancer Inst 2001;93:447-455.
34. Cher DJ, Miyamoto J, Lenert LA. Incorporating risk attitude into Markov-process decision models: importance for individual decision making. Med Decis Making 1997;17:340-350.
35. Glare P, Virik K, Jones M et al. A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ 2003;327:195.
36. Baum M, Ravdin PM. Decision-making in early breast cancer: guidelines and decision tools. Eur J Cancer 2002;38:745-749.
37. Simes RJ, Coates AS. Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed? J Natl Cancer Inst Monogr 2001;30:146-152.
38. Ravdin PM, Siminoff LA, Davis GJ et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980-991.
39. Loprinzi CL, Thome SD. Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 2001;19:972-979.
40. Loprinzi CL, Ravdin PM, de Laurentiis M, Novotny P. Do American oncologists know how to use prognostic variables for patients with newly diagnosed primary breast cancer? J Clin Oncol 1994;12:1422-1426.
41. Loprinzi CL, Laurie JA, Wieand HS et al. Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group. J Clin Oncol 1994;12:601-607.
42. Ravdin PM. A practical view of prognostic factors for staging, adjuvant treatment planning, and as baseline studies for possible future therapy. Hematol Oncol Clin North Am 1994;8:197-211.
43. McGuire WL, Tandon AK, Allred DC, Chamness GC, Ravdin PM, Clark GM. Prognosis and treatment decisions in patients with breast cancer without axillary node involvement. Cancer 1992;70:1775-1781.
44. Siminoff LA, Fetting JH. Factors affecting treatment decisions for a life-threatening illness: the case of medical treatment of breast cancer. Soc Sci Med 1991;32:813-818.
45. Fetting JH, Siminoff LA, Piantadosi S, Abeloff MD, Damron DJ, Sarsfield AM. Effect of patients' expectations of benefit with standard breast cancer adjuvant chemotherapy on participation in a randomized clinical trial: a clinical vignette study. J Clin Oncol 1990;8:1476-1482.
46. Siminoff LA, Fetting JH. Effects of outcome framing on treatment decisions in the real world: impact of framing on adjuvant breast cancer decisions. Med Decis Making 1989;9:262-271.
47. Burke W, Emery J. Genetics education for primary-care providers. Nat Rev Genet 2002;3:561-566.
48. Burke W, Acheson L, Botkin J et al. Genetics in primary care: a USA faculty development initiative. Community Genet 2002;5:138-146.
49. Burke W. Genetic testing in primary care. Annu Rev Genomics Hum Genet 2004;5: 1-14.
50. Gianni L, Zambetti M, Clark K et al. Gene expression profiles of paraffin-embedded core biopsy tissue predict response to chemotherapy in patients with locally advanced breast cancer. Paper presented at: American Society of Clinical Oncology Annual Meeting. New Orleans, June 5-8, 2004.
51. Rutgers EJ, Meijnen P, Bonnefoi H. Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group. Breast Cancer Res 2004;6:165-169.
52. Giordano S, Buzdar A, Shu-Wan C, Hortobagyi G. Improvements in breast cancer survival: results from M.D. Anderson Cancer Center protocols from 1975-2000. Paper presented at: American Society of Clinical Oncology Annual Meeting. Chicago, May 18-20, 2002.
53. Edwards BK, Howe HL, Ries LA et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002;94:2766-2792.
54. de Haes JC, de Koning HJ, van Oortmarssen GJ, van Agt HM, de Bruyn AE, van Der Maas PJ. The impact of a breast cancer screening programme on quality-adjusted life-years. Int J Cancer 1991;49:538-544.
55. Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med 1991;324:160-168.
56. Hillner BE, Smith TJ, Desch CE. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results. JAMA 1992;267:2055-2061.
57. Hayman JA, Fairclough DL, Harris JR, Weeks JC. Patient preferences concerning the trade-off between the risks and benefits of routine radiation therapy after conservative surgery for early-stage breast cancer. J Clin Oncol 1997;15:1252-1260.
58. Hutton J, Brown R, Borowitz M, Abrams K, Rothman M, Shakespeare A. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics 1996;9:8-22.
59. Brown RE, Hutton J, Burrell A. Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics 2001;19:1091-1102.
60. Cosler L, Hornberger J, Lyman G. Economic analysis of targeted chemotherapy using a 21-gene RT-PCR assay in lymph node negative, estrogen receptor positive early-stage breast cancer. Paper presented at: American Society for Clinical Oncology Annual Meeting. New Orleans, June 5-8, 2004.
61. Warren JL, Brown ML, Fay MP, Schussler N, Potosky AL, Riley GF. Costs of treatment for elderly women with early-stage breast cancer in fee-for-service settings. J Clin Oncol 2002;20:307-316.
62. Smith TJ, Hillner BE. The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women. J Clin Oncol 1993;11:771-776.
63. Lokich JJ, Moore CL, Anderson NR. Comparison of costs for infusion versus bolus chemotherapy administration-Part two. Use of charges versus reimbursement for cost basis. Cancer 1996;78:300-303.
64. Taplin SH, Barlow W, Urban N, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995;87:417-426.
65. Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995;33:828-841.
66. Fireman BH, Quesenberry CP, Somkin CP, et al. Cost of care for cancer in a health maintenance organization. Health Care Financ Rev 1997;18:51-76.